Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Tearing of Membranes Before Birth - a Comparison Between Two Ways of Induction of Labor Pitocin Opposite Prostaglandin

25 de mayo de 2016 actualizado por: Tel-Aviv Sourasky Medical Center
Premature rupture of membranes (PROM) is a common occurrence that occurs in the incidence of 8-10% of births. Since the duration until delivery is important in avoiding the risk of complications, several studies have been performed in order to understand what is the preferred way to manage this condition of PROM in women that are not in active labor. In the largest random study that has been performed 20 years ago, there was found an advantage for labor induction with oxytocin over labor induction with Prostaglandin or waiting. However, the most important component - the BISHOP score, that affects the decision of the labor induction way, was not reported and was not taken into consideration.

Descripción general del estudio

Descripción detallada

Premature rupture of membranes (PROM) is a common occurrence that occurs in the incidence of 8-10% of births. Since the duration until delivery is important in avoiding the risk of complications, several studies have been performed in order to understand what is the preferred way to manage this condition of PROM in women that are not in active labor. In the largest random study that has been performed 20 years ago, there was found an advantage for labor induction with oxytocin over labor induction with Prostaglandin or waiting. However, the most important component - the BISHOP score, that affects the decision of the labor induction way, was not reported and was not taken into consideration.

Therefore, the aim of the study is to compare randomly the perinatal outcomes in women with PROM and low BISHOP between women who undergo labor induction with Oxytocin and women who undergo labor induction with Prostaglandin E2.

Tipo de estudio

Intervencionista

Inscripción (Anticipado)

1200

Fase

  • Fase 3

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 42 años (Adulto)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  1. rupture of membranes in BISHOP score lower than 7.
  2. Pregnancy week 34+0 and onward.
  3. Singleton pregnancy.
  4. Verifying fetal monitoring.
  5. Normal maternal temperature (lower than 37.8)
  6. Without vaginal bleeding or suspected placental separation
  7. Contractions in frequency of less than 3 in 10 minutes
  8. Signed consent form.

Exclusion Criteria:

  1. Multiple pregnancy.
  2. Maternal age below 18 or over 42.
  3. Active labor
  4. Contractions in frequency of more than 3 in 10 minutes or cervical dilation ≥2 cm.
  5. Lack of consent to participate in the study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Intravenous oxytocin

Women that arrive to women's ER and diagnosed with rupture of membranes in week 34+0 and onward, are not in active labor and with Bishop score lower than 7.

Those who agreed to participate in the study after signing an informed consent form will undergo the following steps:

  1. Verification rupture of membranes and gestational age.
  2. Choosing the treatment group Intravenous oxytocin from red envelope, randomly.
  3. Collecting basic and obstetric data, laboratory results and physical examination, monitoring and sonar.
  4. Induction according to departmental protocol of each delivery way.
  5. Data collecting after the delivery.

Intravenous oxytocin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.

Induction according to departmental protocol of each delivery way. Data collecting after the delivery.

Experimental: vaginal prostaglandin

Women that arrive to women's ER and diagnosed with rupture of membranes in week 34+0 and onward, are not in active labor and with Bishop score lower than 7.

Those who agreed to participate in the study after signing an informed consent form will undergo the following steps:

  1. Verification rupture of membranes and gestational age.
  2. Choosing the treatment group vaginal prostaglandin from red envelope, randomly.
  3. Collecting basic and obstetric data, laboratory results and physical examination, monitoring and sonar.
  4. Induction according to departmental protocol of each delivery way.
  5. Data collecting after the delivery.

Vaginal prostaglandin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.

Induction according to departmental protocol of each delivery way. Data collecting after the delivery.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
The duration from the beginning of labor induction until delivery
Periodo de tiempo: 5 days
5 days

Medidas de resultado secundarias

Medida de resultado
Periodo de tiempo
Duration of labor induction from rupture of membranes until delivery.
Periodo de tiempo: 5 days
5 days

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Sharon Maslovitz, MD, Tel Aviv Medical Center

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de mayo de 2016

Finalización primaria (Anticipado)

1 de mayo de 2019

Finalización del estudio (Anticipado)

1 de mayo de 2019

Fechas de registro del estudio

Enviado por primera vez

22 de marzo de 2016

Primero enviado que cumplió con los criterios de control de calidad

25 de marzo de 2016

Publicado por primera vez (Estimar)

28 de marzo de 2016

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

26 de mayo de 2016

Última actualización enviada que cumplió con los criterios de control de calidad

25 de mayo de 2016

Última verificación

1 de mayo de 2016

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 0073-15-TLV

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir